Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

Given the unmet need of fatigue in primary biliary cholangitis (PBC), the PBC working group of the European Reference Network for Rare Liver Diseases assessed and summarised the current evidence ...

The European Medicines Agency (EMA) has recommended that a conditional marketing authorization should be granted for Iqirvo (elafibranor; Ipsen Pharma) for treating primary biliary cholangitis (PBC).

NEWARK, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic ...

Please provide your email address to receive an email when new articles are posted on . More patients on elafibranor compared with placebo achieved biochemical response, with a 47% treatment benefit.

Ipsen receives CHMP positive opinions for Iqirvo ® (elafibranor) in Primary Biliary Cholangitis and Kayfanda ® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases PARIS, FRANCE, 26 ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Hepatology Communications published data from the CAMEO study evaluating the safety, tolerability, ...

Pianist Jonathan Delbridge to perform in Crewkerne on 2 Nov, raising funds for PSC Support, the UK’s only primary sclerosing cholangitis charity.

DelveInsight’s, “Primary Biliary Cholangitis Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape.